With its stock in a slump, Moderna makes the case for its big-money valuation
With its stock in a slump, Moderna makes the case for its big-money valuation.
SAN FRANCISCO — Moderna Therapeutics had record-setting success raising money from private investors, but the much-discussed biotech has struggled to convince the public markets of its industry-upending potential, and its stock price has slumped nearly 30 percent in the weeks following what was biotech’s largest-ever initial public offering.
That left Moderna CEO Stéphane Bancel, speaking before a standing-room crowd at the industry’s premiere gathering on Tuesday, with a curious task: convincing investors that
